Squamous cell carcinoma of head and neck
Not recruitingTesting Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned
Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned
- Disease:Squamous cell carcinoma of head and neck
- Substances:DostarlimabGsk4381562A+2
France- Participants:18–64 years · 65+ years
- Substances:Dostarlimab
- Sponsor:Glaxosmithkline Research & Development Limited











